The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: A prospective study

Journal of the American College of Cardiology

Volumn 42, Issue 2, 2003, Pages 211-216

  Fukumoto, Yoshihiro ^a   Tsutsui, Hiroyuki ^a   Tsuchihashi, Miyuki ^a   Masumoto, Akihiro ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; ARTIFICIAL EMBOLISM; ASCENDING AORTA; ATHEROSCLEROSIS; CHOLESTEROL EMBOLIZATION SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GANGRENE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LIVEDO RETICULARIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SYNDROME;

EID: 0038639604     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00579-5     Document Type: Article

References (33)

1. Creager MA, Libby P. Peripheral arterial disease. In: Braunwald E, Zipes D, Libby P, editors. Heart Disease. 6th edition. Philadelphia, PA: Saunders, 2001:1457-84.
2. Feder W, Auerbach R. "Purple toes:" an uncommon sequela of oral coumarin drug therapy. Ann Intern Med 1961;55:911-7.
3. Ramirez G, O'Neill WM, Jr., Lambert R, Bloomer HA. Cholesterol embolization: a complication of angiography. Arch Intern Med 1978; 138:1430-2.
4. Rosansky SJ, Deschamps EG. Multiple cholesterol emboli syndrome after angiography. Am J Med Sci 1984;288:45-8.
5. Drost H, Buis B, Haan D, Hillers JA. Cholesterol embolism as a complication of left heart catheterisation. Report of seven cases. Br Heart J 1984;52:339-42.
6. Hyman BT, Landas SK, Ashman RF, Schelper RL, Robinson RA. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987;82:1233-7.
7. Shapiro LS. Cholesterol embolization after treatment with tissue plasminogen activator. N Engl J Med 1989;321:1270.
8. Bols A, Nevelsteen A, Verhaeghe R. Atheromatous embolization precipitated by oral anticoagulants. Int Angiol 1994;13:271-4.
9. Scolari F, Bracchi M, Valzorio B, et al. Cholesterol atheromatous embolism: an increasingly recognized cause of acute renal failure. Nephrol Dial Transplant 1996;11:1607-12.
10. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998;31:134-8.
11. Davila-Roman VG, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is a predictor of renal dysfunction after cardiac operations. J Thorac Cardiovasc Surg 1999;117: 111-6.
12. Cosio FG, Zager RA, Sharma HM. Atheroemboilc renal disease causes hypocomplementaemia. Lancet 1985;2:118-21.
13. Kasinath BS, Corwin HL, Bidani AK, Korbet SM, Schwartz MM, Lewis EJ. Eosinophilla in the diagnosis of atheroemboilc renal disease. Am J Nephrol 1987;7:173-7.
14. Blankenship JC, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with acute myocardial infarction treated with thrombolytic vs conservative therapy. Chest 1995;107: 662-8.
15. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). J Am Coll Cardiol 2001;37:2215-39.
16. Smith MC, Ghose MK, Henry AR. The clinical spectrum of renal cholesterol embolization. Am J Med 1981;71:174-80.
17. Rosman HS, Davis TP, Reddy D, Goldstein S. Cholesterol embolization: clinical findings and implications. J Am Coll Cardiol 1990;15: 1296-9.
18. Geraets DR, Hoehns JD, Burke TG, Grover-McKay M. Thrombolytic-associated cholesterol emboli syndrome: case report and literature review. Pharmacotherapy 1995;15:441-50.
19. Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med 1991;91:186-9.
20. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987;38:769-84.
21. Libby P, Clinton SK. Cytokines as mediators of vascular pathology. Nouv Rev Fr Hematol 1992;34:S47-53.
22. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-8.
23. Fukumoto Y, Shimokawa H, Kozai T, et al. Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1 beta in pigs in vivo. Circulation 1997;96:3104-11.
24. Ridker PM. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis 1997; 27:2-11.
25. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-9.
26. Aikawa M, Libby P. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 2000;902:140-52.
27. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 1998;98:839-44.
28. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
29. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
30. Bruns FJ, Segel DP, Adler S. Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci 1978;275: 105-8.
31. Thadhani RI, Camargo CA, Jr, Xavier RJ, Fang LS, Bazari H. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995; 74:350-8.
32. Blackshear JL, Zabalgoitia M, Pennock G, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal Echocardiography. Am J Cardiol 1999;83:453-5.
33. Oda H, Miida T, Sato H, Higuma N. Treatment of unstable angina with cholesterol embolization as a complication of left heart catheterization. Jpn Circ J 1990;54:487-92.